Baxter's (BAX, $77.90) Q3 revenue misses expectations, according to preliminary report
Baxter International Inc. reported preliminary third-quarter 2019 revenues of $2.85 billion, which were lower than the Zacks Consensus Estimate of $2.86 billion. However, the figure was +3% higher compared to the year-ago quarter, on a reported basis. (+5% on both constant currency and operational basis).
Revenues in Americas were up +2.5% on a year-over-year basis, according to the preliminary results.
In EMEA, revenues increased + 3.3% from the year-ago quarter.
APAC revenues rose +4.3% from the prior-year quarter.
Baxter’s Renal Care segment generated revenues of $918 million in the quarter under review, up +0.9% year-over-year. Medication Delivery unit’s revenues increased +7.5% to $701 million. Pharmaceuticals revenues came in at $527 million, up +1.5% from the year-ago quarter. Clinical Nutrition revenues at the segment rose +0.5% to $219 million. Revenues from Advanced Surgery segment were $216 million, up +8%. Acute Therapies segment revenues of $130 million, were up +6.6% from the prior-year quarter.
Other revenues in the segment totaled $140 million, down -4.1% on a year-over-year basis.
Baxter’s preliminary adjusted gross margin contracted - 60 bps to 45.7% in the third quarter. Preliminary operating margin expanded +370 bps to 17.6% in the quarter.
According to the preliminary report, Baxter expects fourth quarter 2019 revenues to grow in the range of +3-4% on a reported basis, and approximately +5% on both constant currency and operational basis.
The company predicts that operating margin would range between 15.2% and 15.9% on a reported basis, and 18.5-19% on an adjusted basis.
BAX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for BAX moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 47 similar instances where the indicator exited the overbought zone. In of the 47 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BAX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BAX's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on August 14, 2025. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 181 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.683) is normal, around the industry mean (11.051). P/E Ratio (87.846) is within average values for comparable stocks, (57.884). Projected Growth (PEG Ratio) (1.997) is also within normal values, averaging (1.748). Dividend Yield (0.028) settles around the average of (0.016) among similar stocks. P/S Ratio (1.128) is also within normal values, averaging (17.078).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices
Industry PharmaceuticalsOther
Advertisement